AU3108097A - 4-phenylpiperidine compounds - Google Patents
4-phenylpiperidine compounds Download PDFInfo
- Publication number
- AU3108097A AU3108097A AU31080/97A AU3108097A AU3108097A AU 3108097 A AU3108097 A AU 3108097A AU 31080/97 A AU31080/97 A AU 31080/97A AU 3108097 A AU3108097 A AU 3108097A AU 3108097 A AU3108097 A AU 3108097A
- Authority
- AU
- Australia
- Prior art keywords
- group
- alkyl
- compound according
- acid
- paroxetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical class C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 27
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- -1 methylsulphonyl Chemical group 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims abstract description 6
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 5
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims abstract description 5
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 60
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 44
- 229960002296 paroxetine Drugs 0.000 claims description 40
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- AEIUZSKXSWGSRU-QXGDPHCHSA-N paroxetine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AEIUZSKXSWGSRU-QXGDPHCHSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- RQBJOWKBGCDPOS-RVXRQPKJSA-N acetic acid;(3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound CC(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 RQBJOWKBGCDPOS-RVXRQPKJSA-N 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 201000000484 premenstrual tension Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 2
- XQQINDIFTCMFSK-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;hydrobromide;hydrochloride Chemical compound Cl.Br.OC(=O)CC(O)(C(O)=O)CC(O)=O XQQINDIFTCMFSK-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- YHXMBBHLAOUQJP-UHFFFAOYSA-N OC(=O)C(O)=O.OC(=O)CCC(O)=O.OC(C(O)C(O)=O)C(O)=O Chemical compound OC(=O)C(O)=O.OC(=O)CCC(O)=O.OC(C(O)C(O)=O)C(O)=O YHXMBBHLAOUQJP-UHFFFAOYSA-N 0.000 claims 1
- VCAQPYXOWLIOSF-UHFFFAOYSA-N acetic acid;sulfuric acid;hydrate Chemical compound O.CC(O)=O.OS(O)(=O)=O VCAQPYXOWLIOSF-UHFFFAOYSA-N 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 229910052799 carbon Inorganic materials 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- SHIJTGJXUHTGGZ-RVXRQPKJSA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidin-1-ium;methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 SHIJTGJXUHTGGZ-RVXRQPKJSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940093499 ethyl acetate Drugs 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 150000003460 sulfonic acids Chemical class 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CAQZTSCRGMRSHX-ODZAUARKSA-N (z)-but-2-enedioic acid;ethanol Chemical compound CCO.OC(=O)\C=C/C(O)=O CAQZTSCRGMRSHX-ODZAUARKSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SWEGYVABIIPISO-NFMYELBMSA-N O.C(\C=C\C(=O)O)(=O)O.O.C(\C=C\C(=O)O)(=O)O.O Chemical compound O.C(\C=C\C(=O)O)(=O)O.O.C(\C=C\C(=O)O)(=O)O.O SWEGYVABIIPISO-NFMYELBMSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ULAHIHHGQVIRTO-UHFFFAOYSA-N methanesulfonic acid;4-methylbenzenesulfonic acid Chemical compound CS(O)(=O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 ULAHIHHGQVIRTO-UHFFFAOYSA-N 0.000 description 1
- KNTNVFMMGRLMKU-UHFFFAOYSA-N n,n-diethylethanamine;n-methylmethanamine Chemical compound CNC.CCN(CC)CC KNTNVFMMGRLMKU-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002301956A AU2002301956B2 (en) | 1997-06-10 | 2002-11-12 | 4-phenylpiperidine compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/872,023 US5874447A (en) | 1997-06-10 | 1997-06-10 | 4-Phenylpiperidine compounds for treating depression |
| PCT/NL1997/000328 WO1998056787A1 (en) | 1997-06-10 | 1997-06-10 | 4-Phenylpiperidine compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002301956A Division AU2002301956B2 (en) | 1997-06-10 | 2002-11-12 | 4-phenylpiperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3108097A true AU3108097A (en) | 1998-12-30 |
Family
ID=26647319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31080/97A Abandoned AU3108097A (en) | 1997-06-10 | 1997-06-10 | 4-phenylpiperidine compounds |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US5874447A (OSRAM) |
| EP (2) | EP1078925A1 (OSRAM) |
| JP (1) | JP2002503248A (OSRAM) |
| KR (1) | KR100543614B1 (OSRAM) |
| AT (1) | ATE200781T1 (OSRAM) |
| AU (1) | AU3108097A (OSRAM) |
| BG (1) | BG64315B1 (OSRAM) |
| BR (1) | BR9714787A (OSRAM) |
| CA (1) | CA2293247C (OSRAM) |
| CZ (1) | CZ295301B6 (OSRAM) |
| DE (2) | DE29724281U1 (OSRAM) |
| DK (1) | DK0994872T3 (OSRAM) |
| EE (2) | EE03970B1 (OSRAM) |
| ES (1) | ES2155995T3 (OSRAM) |
| GR (1) | GR3035784T3 (OSRAM) |
| HU (1) | HUP0003141A3 (OSRAM) |
| IL (1) | IL133366A (OSRAM) |
| IS (2) | IS1927B (OSRAM) |
| NO (3) | NO317371B1 (OSRAM) |
| PL (1) | PL188450B1 (OSRAM) |
| PT (1) | PT994872E (OSRAM) |
| SI (1) | SI0994872T1 (OSRAM) |
| SK (1) | SK283394B6 (OSRAM) |
| TR (2) | TR200201156T2 (OSRAM) |
| WO (1) | WO1998056787A1 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713131B3 (en) * | 1998-07-02 | 1999-11-25 | Smithkline Beecham Plc | Novel compound |
| AU724845B3 (en) * | 1998-07-02 | 2000-09-28 | Smithkline Beecham Plc | Novel compound |
| AU727000B3 (en) * | 1999-06-22 | 2000-11-30 | Smithkline Beecham Plc | Novel composition |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221921B1 (hu) * | 1996-07-08 | 2003-02-28 | Richter Gedeon Vegyészeti Gyár Rt. | N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására |
| KR20010042552A (ko) * | 1998-04-09 | 2001-05-25 | 피터 기딩스 | 파록세틴 말레에이트 |
| US20010023252A1 (en) * | 1998-07-02 | 2001-09-20 | Smithkline Beecham Plc | Novel compound |
| GB9814316D0 (en) * | 1998-07-02 | 1998-09-02 | Smithkline Beecham Plc | Novel compounds |
| WO2000008016A1 (en) * | 1998-08-08 | 2000-02-17 | Smithkline Beecham Plc | Paroxetine salts |
| GB9827431D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
| GB9828780D0 (en) * | 1998-12-29 | 1999-02-17 | Smithkline Beecham Plc | Novel process |
| GB9828779D0 (en) * | 1998-12-29 | 1999-02-17 | Smithkline Beecham Plc | Novel process |
| GB9828781D0 (en) * | 1998-12-29 | 1999-02-17 | Smithkline Beecham Plc | Novel process |
| WO2000078290A2 (en) * | 1999-06-22 | 2000-12-28 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a salt of paroxetine |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| DK1109806T3 (da) * | 1999-07-01 | 2003-12-22 | Italfarmaco Spa | Komplekser af paroxetin med cyclodextriner eller cyclodextrinderivater |
| GB9919052D0 (en) * | 1999-08-12 | 1999-10-13 | Smithkline Beecham Plc | Novel compound composition and process |
| US6503927B1 (en) * | 1999-10-28 | 2003-01-07 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EP1280775A1 (en) * | 2000-05-12 | 2003-02-05 | Synthon B.V. | TOSYLATE SALTS OF 4-(p-FLUOROPHENYL)-PIPERIDINE-3-CARBINOLS |
| DE60007782T2 (de) * | 2000-05-12 | 2004-12-09 | Synthon B.V. | Piperidinverbindungen und verfahren zu deren herstellung |
| IL154422A0 (en) * | 2000-08-28 | 2003-09-17 | Synthon Bv | Paroxetine compositions and processes for making the same |
| JPWO2002022609A1 (ja) * | 2000-09-14 | 2004-01-22 | 旭硝子株式会社 | 実質的に有機溶媒を含まないパロキセチン塩類の製造方法 |
| DE20100529U1 (de) * | 2001-01-11 | 2001-05-10 | Synthon Bv | Pharmazeutische Tablette umfassend Paroxetinmesylat |
| US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| NL1017421C2 (nl) * | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| US20030032809A1 (en) * | 2001-04-25 | 2003-02-13 | Subhash P. Upadhyaya | Optimized procedures for the manufacture of paroxetine salts |
| CA2457382A1 (en) * | 2001-06-13 | 2002-12-19 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of paroxetine substantially free of alkoxy impurities |
| IL159280A0 (en) * | 2001-06-14 | 2004-06-01 | Teva Pharma | A process for preparing paroxetine hcl which limits formation of pink colored compounds |
| WO2003020717A1 (en) * | 2001-08-02 | 2003-03-13 | Spurcourt Limited | Paroxetine isethionate salt, process of preparation and use in the treatment of depression |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| AR039163A1 (es) * | 2002-03-28 | 2005-02-09 | Synthon Bv | Besilato de venlafaxina |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| JP5646126B2 (ja) | 2003-12-11 | 2014-12-24 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法 |
| WO2006018318A1 (en) * | 2004-08-18 | 2006-02-23 | Synthon B.V. | Liquid paroxetine compositions |
| EP1791531A1 (en) * | 2004-08-20 | 2007-06-06 | Alpharma, Inc. | Paroxetine formulations |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| CA2616383C (en) * | 2005-07-29 | 2015-06-09 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| CN101855218A (zh) * | 2007-09-13 | 2010-10-06 | 康塞特医药品有限公司 | 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 |
| US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
| US20120077842A1 (en) | 2009-08-19 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013216123B2 (en) * | 2012-01-31 | 2016-10-20 | Eisai R&D Management Co., Ltd. | Paroxetine derivative |
| EP2844346B1 (en) | 2012-04-04 | 2020-01-01 | Prilenia Neurotherapeutics Ltd. | Pharmaceutical compositions for combination therapy |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| WO2016136745A1 (ja) | 2015-02-25 | 2016-09-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| EP3338779B1 (en) | 2015-08-20 | 2021-06-30 | Eisai R&D Management Co., Ltd. | Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor |
| AU2018219637B2 (en) | 2017-02-08 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT99678B (de) * | 1921-09-21 | 1925-04-10 | Hoechst Ag | Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen. |
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4585777A (en) * | 1984-02-07 | 1986-04-29 | A/S Ferrosan | (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT |
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| EP0190496A3 (en) * | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
| GB8520154D0 (en) * | 1985-08-10 | 1985-09-18 | Beecham Group Plc | Chemical process |
| EP0223334B1 (en) * | 1985-08-10 | 1991-07-10 | Beecham Group Plc | Process for the preparation of aryl-piperidine carbinols |
| DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
| US5258388A (en) | 1986-03-17 | 1993-11-02 | University Of Florida | Anticholinergic compounds, compositions and methods of treatment |
| IE66332B1 (en) * | 1986-11-03 | 1995-12-27 | Novo Nordisk As | Piperidine compounds and their preparation and use |
| GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
| GB8714707D0 (en) * | 1987-06-23 | 1987-07-29 | Beecham Group Plc | Chemical process |
| DK716088D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Reduktion af piperidin-dion-derivater samt intermediat |
| DK715988D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Etherifikation og dealkylering af piperidin-derivater samt intermediater |
| CA2096853A1 (en) * | 1990-11-24 | 1992-05-25 | Anthony Michael Johnson | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
| GB9209687D0 (en) * | 1992-05-06 | 1992-06-17 | Smithkline Beecham Plc | Novel process |
| US5258517A (en) * | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
| JP2773587B2 (ja) * | 1992-11-30 | 1998-07-09 | 東レ株式会社 | Ｏ，ｏ´−ジアシル酒石酸無水物の製造法 |
| US5276042A (en) | 1993-04-16 | 1994-01-04 | Crenshaw Roger T | Treatment of premature ejaculation |
| US5546683A (en) * | 1993-09-29 | 1996-08-20 | Clark; George J. | Bucket attachment device with remote controlled retractable pins |
| IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
| GB9325644D0 (en) | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
| US5668134A (en) * | 1994-01-28 | 1997-09-16 | G. D. Searle & Co. | Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications |
| GB9402029D0 (en) * | 1994-02-03 | 1994-03-30 | Smithkline Beecham Plc | Novel formulation |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| JPH08220486A (ja) * | 1994-12-14 | 1996-08-30 | Kato Kogei:Kk | 眼鏡フレーム |
| GB2297550C2 (en) * | 1995-02-06 | 1997-04-09 | Smithkline Beecham Plc | Paroxetine hydrochloride anhydrate substantially free of bound organic solvent |
| SK283608B6 (sk) * | 1995-02-06 | 2003-10-07 | Smithkline Beecham Plc | Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie |
| US5856493A (en) * | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
| EP0818990A1 (en) * | 1995-04-03 | 1998-01-21 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
| HUP9900318A3 (en) * | 1995-05-17 | 2001-09-28 | Novo Nordisk As | Process for preparing 4-aryl-piperidine derivatives |
| JP2813768B2 (ja) * | 1995-05-24 | 1998-10-22 | 農林水産省家畜衛生試験場長 | 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原 |
| GB9514842D0 (en) * | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| CA2234640A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Process for preparing substituted azetidinones |
| IT1276160B1 (it) * | 1995-11-22 | 1997-10-27 | Recordati Chem Pharm | Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee |
| GB9526645D0 (en) * | 1995-12-28 | 1996-02-28 | Chiroscience Ltd | Stereoselective synthesis |
| ES2117557B1 (es) * | 1996-02-29 | 1999-07-01 | Ferrer Int | Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina. |
| JP3446468B2 (ja) * | 1996-04-15 | 2003-09-16 | 旭硝子株式会社 | ピペリジンカルビノール類の製造方法 |
| CA2206592A1 (en) * | 1996-05-30 | 1997-11-30 | Shu-Zhong Wang | Method of producing amorphous paroxetine hydrochloride |
| JP3882224B2 (ja) * | 1996-05-31 | 2007-02-14 | 旭硝子株式会社 | パロキセチンの製造方法 |
| EP1384711A1 (en) * | 1996-06-13 | 2004-01-28 | SUMIKA FINE CHEMICALS Co., Ltd. | Optical resolution of a piperidine derivative |
| HU221921B1 (hu) * | 1996-07-08 | 2003-02-28 | Richter Gedeon Vegyészeti Gyár Rt. | N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására |
| US5672609A (en) * | 1996-07-18 | 1997-09-30 | Eli Lilly And Company | Pyridine compounds, intermediates compositions and methods of use |
| CA2187128A1 (en) * | 1996-10-04 | 1997-06-26 | K. S. Keshava Murthy | New and useful polymorph of anhydrous paroxetine hydrochloride |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| CH689805A8 (fr) | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
-
1997
- 1997-06-10 SI SI9730138T patent/SI0994872T1/xx unknown
- 1997-06-10 ES ES97926276T patent/ES2155995T3/es not_active Expired - Lifetime
- 1997-06-10 CA CA002293247A patent/CA2293247C/en not_active Expired - Lifetime
- 1997-06-10 JP JP50212699A patent/JP2002503248A/ja not_active Ceased
- 1997-06-10 PL PL97336895A patent/PL188450B1/pl not_active IP Right Cessation
- 1997-06-10 SK SK1619-99A patent/SK283394B6/sk unknown
- 1997-06-10 EE EEP199900570A patent/EE03970B1/xx not_active IP Right Cessation
- 1997-06-10 WO PCT/NL1997/000328 patent/WO1998056787A1/en not_active Ceased
- 1997-06-10 DE DE29724281U patent/DE29724281U1/de not_active Expired - Lifetime
- 1997-06-10 EP EP00203910A patent/EP1078925A1/en not_active Withdrawn
- 1997-06-10 CZ CZ19994295A patent/CZ295301B6/cs not_active IP Right Cessation
- 1997-06-10 IL IL13336697A patent/IL133366A/xx not_active IP Right Cessation
- 1997-06-10 DE DE69704679T patent/DE69704679T2/de not_active Expired - Lifetime
- 1997-06-10 KR KR1019997011625A patent/KR100543614B1/ko not_active Expired - Fee Related
- 1997-06-10 US US08/872,023 patent/US5874447A/en not_active Expired - Lifetime
- 1997-06-10 TR TR2002/01156T patent/TR200201156T2/xx unknown
- 1997-06-10 DK DK97926276T patent/DK0994872T3/da active
- 1997-06-10 TR TR1999/03025T patent/TR199903025T2/xx unknown
- 1997-06-10 HU HU0003141A patent/HUP0003141A3/hu unknown
- 1997-06-10 BR BR9714787-7A patent/BR9714787A/pt unknown
- 1997-06-10 EP EP97926276A patent/EP0994872B9/en not_active Expired - Lifetime
- 1997-06-10 EE EEP200200633A patent/EE200200633A/xx unknown
- 1997-06-10 AT AT97926276T patent/ATE200781T1/de not_active IP Right Cessation
- 1997-06-10 AU AU31080/97A patent/AU3108097A/en not_active Abandoned
- 1997-06-10 PT PT97926276T patent/PT994872E/pt unknown
-
1998
- 1998-11-30 US US09/200,743 patent/US7598271B1/en not_active Expired - Lifetime
-
1999
- 1999-11-08 NO NO19995455A patent/NO317371B1/no unknown
- 1999-11-16 IS IS5249A patent/IS1927B/is unknown
- 1999-12-10 BG BG103980A patent/BG64315B1/bg unknown
-
2001
- 2001-04-26 GR GR20010400220T patent/GR3035784T3/el not_active IP Right Cessation
- 2001-05-16 US US09/855,710 patent/US6900327B2/en not_active Expired - Lifetime
-
2003
- 2003-08-25 NO NO20033765A patent/NO20033765D0/no not_active Application Discontinuation
- 2003-08-25 NO NO20033766A patent/NO20033766D0/no not_active Application Discontinuation
-
2004
- 2004-01-08 IS IS7098A patent/IS7098A/is unknown
-
2009
- 2009-01-23 US US12/358,997 patent/US20090326233A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713131B3 (en) * | 1998-07-02 | 1999-11-25 | Smithkline Beecham Plc | Novel compound |
| AU713877B3 (en) * | 1998-07-02 | 1999-12-09 | Smithkline Beecham Plc | Novel compound |
| AU724845B3 (en) * | 1998-07-02 | 2000-09-28 | Smithkline Beecham Plc | Novel compound |
| AU727000B3 (en) * | 1999-06-22 | 2000-11-30 | Smithkline Beecham Plc | Novel composition |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5874447A (en) | 4-Phenylpiperidine compounds for treating depression | |
| US4721723A (en) | Anti-depressant crystalline paroxetine hydrochloride hemihydrate | |
| JP3220266B2 (ja) | アザヘテロサイクリルメチル−クロマン | |
| JP3022951B2 (ja) | アロイル−ピペリジン誘導体 | |
| JP2003528046A (ja) | フェノキシプロパノールアミン類、それらの製造および治療的使用 | |
| CA2404475A1 (en) | Phenylsulphonylpiperazinyl derivatives as 5-ht receptor ligands | |
| JPS6222985B2 (OSRAM) | ||
| FR2549058A1 (fr) | Nouveaux derives de la 1,4-dihydropyridine, leur preparation et leur utilisation comme medicaments | |
| US5071858A (en) | Antipsychotic benzothiopyranylamines | |
| CA2046005A1 (en) | Benzhydryl derivatives having calmodulin inhibitor properties | |
| JPH0135822B2 (OSRAM) | ||
| JPH03120271A (ja) | 抗虚血活性を有するフェニルアルキルアミン誘導体 | |
| AU2002301956B2 (en) | 4-phenylpiperidine compounds | |
| CN1092654C (zh) | 4－苯基哌啶类化合物 | |
| MXPA99011355A (en) | 4-phenylpiperidine compounds | |
| CA2455954A1 (en) | 4-phenylpiperidine compounds | |
| JP2003535845A (ja) | プロパノールアミノテトラリン類、その製造及びそれらを含む組成物 | |
| DK200000380U1 (da) | 4-phenyl-piperidin-forbindelser | |
| HK1027352B (en) | 4-phenylpiperidine compounds | |
| WO2001025201A1 (en) | Process for the preparation of paroxetin intermediate | |
| FR2663329A1 (fr) | Composes aromatiques amines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| SI21067A2 (sl) | Amlodipin hemimaleat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |